Abveris Webinar: Excellence in Anti-Idiotype Antibody Discovery
Anti-Idiotype mAbs by Abveris - Ideal reagents for PK/ADA assays

00:40:00

Nov 13, 2019 01:52 PM

Abveris Logo
* Required information
Loading

Speakers

Tracey Mullen
COO @Abveris
Tracey Mullen is a chemical-biological engineer from MIT who began her career as an Antibody Discovery Scientist at a startup contract research organization specializing in in vivo antibody discovery. In 2013, she joined the Antibody Discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Throughout her tenure at Biogen, Tracey worked to optimize the in vitro discovery of antibodies to tough targets, including leveraging the Adimab platform to generate antibodies against GPCRs. In June of 2018, Tracey joined Abveris Antibody as the Director of Antibody Discovery Operations, where she managed project design and development for in vivo discovery projects before assuming the role of Chief Operating Officer.